What is the main purpose of the new collaborative research agreement between Alivexis and Astellas Pharma?

The main purpose is to discover new small molecule compounds and create innovative therapeutic drugs for drug target molecules selected by Astellas, utilizing Alivexis' computational drug discovery platform, including ModBind™.

When was the second collaborative research agreement between Alivexis and Astellas Pharma announced?

The second collaborative research agreement between Alivexis and Astellas Pharma was announced on March 26, 2026.

What is ModBind™ and what is its key capability?

ModBind™ is a physics-based simulation technology independently developed by Alivexis that predicts the binding strength between small molecule compounds and target proteins with high speed and accuracy, without requiring experimental biological activity data.

What role will Alivexis play in this collaborative research?

Alivexis will be responsible for integrated drug discovery research, including in silico evaluation using their computational drug discovery platform, establishing experimental systems, and designing, synthesizing, and evaluating compounds.

What is Astellas Pharma's role and option in this collaboration?

Astellas Pharma will select drug target molecules and will acquire an option on the research results generated from this collaborative research.

AI News NQ Analysis

Alivexis and Astellas Pharma Announce Collaborative Research on New Drug Discovery Targets

NQ Score 56/100

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the main purpose of the new collaborative research agreement between Alivexis and Astellas Pharma?: A: The main purpose is to discover new small molecule compounds and create innovative therapeutic drugs for drug target molecules selected by Astellas, utilizing Alivexis' computational drug discovery platform, including ModBind™.
Q: When was the second collaborative research agreement between Alivexis and Astellas Pharma announced?: A: The second collaborative research agreement between Alivexis and Astellas Pharma was announced on March 26, 2026.
Q: What is ModBind™ and what is its key capability?: A: ModBind™ is a physics-based simulation technology independently developed by Alivexis that predicts the binding strength between small molecule compounds and target proteins with high speed and accuracy, without requiring experimental biological activity data.
Q: What role will Alivexis play in this collaborative research?: A: Alivexis will be responsible for integrated drug discovery research, including in silico evaluation using their computational drug discovery platform, establishing experimental systems, and designing, synthesizing, and evaluating compounds.
Q: What is Astellas Pharma's role and option in this collaboration?: A: Astellas Pharma will select drug target molecules and will acquire an option on the research results generated from this collaborative research.